コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 iomarkers to identify MF without reliance on cardiovascular magnetic resonance.
2 ue-Doppler imaging and speckle tracking, and cardiovascular magnetic resonance.
3 ather than extracellular mass as measured by cardiovascular magnetic resonance.
4 on the right ventricle by contrast-enhanced cardiovascular magnetic resonance.
5 le in preserved left ventricular function by cardiovascular magnetic resonance.
6 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance.
7 d stress states, using oxygenation-sensitive cardiovascular magnetic resonance.
8 cm(2)]) underwent ECG, echocardiography, and cardiovascular magnetic resonance.
9 derwent combined cardiac catheterization and cardiovascular magnetic resonance.
10 eptal curvature was measured using real-time cardiovascular magnetic resonance.
11 250 consecutive DCM patients with the use of cardiovascular magnetic resonance.
12 individuals 20 to 39 years of age underwent cardiovascular magnetic resonance.
13 obal longitudinal strain both measured using cardiovascular magnetic resonance.
14 quantitative serial perfusion imaging using cardiovascular magnetic resonance.
15 ECGs were obtained within 7.8+/-8.3 weeks of cardiovascular magnetic resonance.
16 and myocardial area at risk were measured by cardiovascular magnetic resonance.
17 nsion not readily detectable by conventional cardiovascular magnetic resonance.
18 intravenous dobutamine administration using cardiovascular magnetic resonance.
19 tively recruited for prior 3-dimensional LGE cardiovascular magnetic resonance.
20 ilure randomized to ICD or control underwent cardiovascular magnetic resonance.
21 These are quantifiable by multiparametric cardiovascular magnetic resonance.
22 tolic dysfunction using the gold standard of cardiovascular magnetic resonance.
23 mass index [BMI], 15.3-59.2 kg/m2) underwent cardiovascular magnetic resonance (1.5 T) to measure RV
24 were retrospectively reviewed (median age at cardiovascular magnetic resonance, 15.4 years; 66.8% mal
25 tissue characterization in particular gives cardiovascular magnetic resonance a prime role among all
27 e blood flow is proposed and adapted to both cardiovascular magnetic resonance and echocardiographic
29 r outcomes in 1293 HCM patients referred for cardiovascular magnetic resonance and followed up for a
31 een location and extent of RV LGE at in vivo cardiovascular magnetic resonance and histologically doc
32 quiring surgical valve replacement underwent cardiovascular magnetic resonance and intraoperative bio
33 iographically successful PCI predicts MVI at cardiovascular magnetic resonance and reduced myocardial
34 e patients (aged 27+/-7 years) underwent LGE cardiovascular magnetic resonance and were followed for
35 Patients were evaluated by echocardiography, cardiovascular magnetic resonance, and (11)C-acetate pos
36 uding late enhancement, equilibrium contrast cardiovascular magnetic resonance, and clinical cardiac
41 spectively enrolled and repeatedly underwent cardiovascular magnetic resonance at 1.5 T seven days (5
42 l structure and function were assessed using cardiovascular magnetic resonance at 1.5-T in treated HI
43 ion myocardial infarction patients underwent cardiovascular magnetic resonance at 4+/-2 days post pri
44 rated animals (Shams; n=3) were imaged using cardiovascular magnetic resonance at similar time points
45 resented with late gadolinium enhancement on cardiovascular magnetic resonance at the right ventricle
47 Use of blood oxygenation level-dependent cardiovascular magnetic resonance (BOLD-CMR) to assess p
48 fined with late gadolinium enhancement (LGE) cardiovascular magnetic resonance but whether this relat
49 ricular mass index using echocardiography or cardiovascular magnetic resonance, but neither quantifie
51 estigated whether multiparametric imaging by cardiovascular magnetic resonance can detect differences
52 pectively underwent same day multiparametric cardiovascular magnetic resonance (cine, T2* iron, vasod
53 sional (3D) whole heart myocardial perfusion cardiovascular magnetic resonance (CMR) against invasive
54 he relation of BMI to LV mass, determined by cardiovascular magnetic resonance (CMR) and heart failur
55 oninvasive imaging methods of fibrosis using cardiovascular magnetic resonance (CMR) and nuclear imag
56 this study was to compare fully quantitative cardiovascular magnetic resonance (CMR) and positron emi
57 re no prospective, prognostic data comparing cardiovascular magnetic resonance (CMR) and single-photo
58 d the sex-specific diagnostic performance of cardiovascular magnetic resonance (CMR) and single-photo
63 with follow-up until December 14, 2015, at a cardiovascular magnetic resonance (CMR) center serving a
65 ed to identify the optimal cut-off of TEI by cardiovascular magnetic resonance (CMR) for defining via
66 he diagnostic performance of multiparametric cardiovascular magnetic resonance (CMR) for detecting ca
67 heterogeneous tissue (HT) channel defined in cardiovascular magnetic resonance (CMR) has been suggest
68 nary angiography, and, most recently, stress cardiovascular magnetic resonance (CMR) have enhanced th
73 ecent case reports using delayed-enhancement cardiovascular magnetic resonance (CMR) imaging raise th
74 pared the diagnostic accuracy of postmortem, cardiovascular magnetic resonance (CMR) imaging with con
76 cement (MWHE) on late gadolinium enhancement cardiovascular magnetic resonance (CMR) imaging, predict
77 aluate ventricular size in HT patients using cardiovascular magnetic resonance (CMR) imaging, to find
78 ricular contraction patterns were defined by cardiovascular magnetic resonance (CMR) imaging, usually
79 tanding of the reader on the applications of cardiovascular magnetic resonance (CMR) in transcatheter
81 ue heterogeneity of myocardial infarction by cardiovascular magnetic resonance (CMR) is associated wi
85 ejection fraction <40%) referred for stress cardiovascular magnetic resonance (CMR) may have a less
86 tudy sought to determine the relationship of cardiovascular magnetic resonance (CMR) measures of tiss
87 validate the four-dimensional flow (4D flow) cardiovascular magnetic resonance (CMR) methods for AS a
92 dy, we assessed the diagnostic accuracy of a cardiovascular magnetic resonance (CMR) protocol incorpo
93 the diagnostic accuracy of a multiparametric cardiovascular magnetic resonance (CMR) protocol with x-
94 own or suspected myocardial infarction (MI), cardiovascular magnetic resonance (CMR) provides a compr
96 hree healthy participants received a 4D flow cardiovascular magnetic resonance (CMR) scan on 1.5 T Ph
97 athletes, and 20 healthy controls underwent cardiovascular magnetic resonance (CMR) scanning at 3-T.
99 ance of novel quantitative T1 and T2 mapping cardiovascular magnetic resonance (CMR) techniques to id
100 tion of left ventricular (LV) hypertrophy by cardiovascular magnetic resonance (CMR) to more precisel
105 inferobasal myocardium have been detected by cardiovascular magnetic resonance (CMR), but the extent
112 and computer simulations showed that CP-BOLD cardiovascular magnetic resonance could be useful in det
113 fusion territories using CE-SSFP and T2-STIR cardiovascular magnetic resonance data in patients after
114 ls from the UK Biobank with paired lipid and cardiovascular magnetic resonance data was performed.
118 imodal cardiac assessment: contrast-enhanced cardiovascular magnetic resonance, echocardiograms, 24-h
119 rs (age, 4-57 years) free from PVR underwent cardiovascular magnetic resonance, echocardiography, and
121 DI] S-wave R=0.52, P<0.001) and conventional cardiovascular magnetic resonance (eg, indexed left vent
123 tion, little information is available on the cardiovascular magnetic resonance findings in this popul
127 drop at the aortic valve using 3-dimensional cardiovascular magnetic resonance flow data in 32 subjec
129 LVEDV) and LV end-systolic volume (LVESV) by cardiovascular magnetic resonance following ST-segment-e
130 thy without history of CHF were studied with cardiovascular magnetic resonance for late gadolinium en
131 % and extracardiac sarcoidosis who underwent cardiovascular magnetic resonance for LGE evaluation.
132 patients (mean age, 40+/-9 years) underwent cardiovascular magnetic resonance for routine assessment
133 osis detected by late gadolinium enhancement cardiovascular magnetic resonance for the prediction of
134 stem, and externally irrigated ablation with cardiovascular magnetic resonance guidance to undertake
138 ed whether late gadolinium enhancement (LGE) cardiovascular magnetic resonance identified patients wi
139 ts) using invasive pressure measurements and cardiovascular magnetic resonance images and subsequentl
140 t trabeculae measured by fractal analysis of cardiovascular magnetic resonance images are abnormal in
142 al signal intensity in oxygenation-sensitive cardiovascular magnetic resonance images of the midapica
143 First-pass CT images and contrast-enhanced cardiovascular magnetic resonance images were acquired i
146 lood lactate analysis, and contrast-enhanced cardiovascular magnetic resonance imaging (cine, tagging
148 he assessment of valvular heart disease, but cardiovascular magnetic resonance imaging (CMR) provides
150 arization: one involves myocardial-perfusion cardiovascular magnetic resonance imaging (MRI), and the
153 puts are left ventricular volume curves from cardiovascular magnetic resonance imaging and brachial p
154 ass and systolic and diastolic function with cardiovascular magnetic resonance imaging and echocardio
155 with healed myocardial infarction underwent cardiovascular magnetic resonance imaging and electroana
157 perglycemia on myocardial damage assessed by cardiovascular magnetic resonance imaging and to evaluat
158 sional speckle tracking echocardiography and cardiovascular magnetic resonance imaging at 1.5 Tesla (
160 (% left ventricular mass) was determined by cardiovascular magnetic resonance imaging at 2 to 7 days
164 s with a history of frequent PVCs undergoing cardiovascular magnetic resonance imaging had real-time
168 is identified by late gadolinium enhancement cardiovascular magnetic resonance imaging in approximate
169 dial fibrosis on late gadolinium enhancement cardiovascular magnetic resonance imaging in heart trans
172 omplicated pericarditis; 2) in select cases, cardiovascular magnetic resonance imaging may aid in the
174 t-elevation myocardial infarction, underwent cardiovascular magnetic resonance imaging on day 3 and m
175 -diastolic volume index measured by means of cardiovascular magnetic resonance imaging or multirow de
176 ction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patient
178 rformed using a 2-dimensional (2D) real-time cardiovascular magnetic resonance imaging technique.
180 This review will highlight some recent novel cardiovascular magnetic resonance imaging techniques, co
181 5% with >5.7% late gadolinium enhancement on cardiovascular magnetic resonance imaging was as sensiti
183 uterized tomographic coronary angiogram, and cardiovascular magnetic resonance imaging with late gado
184 he cardiac cycle in healthy volunteers using cardiovascular magnetic resonance imaging, and (c) to ca
185 ecutive heart transplant recipients that had cardiovascular magnetic resonance imaging, we determined
186 rs; interquartile range, 18 years) underwent cardiovascular magnetic resonance imaging, which was per
200 trophic cardiomyopathy phenotype measured by cardiovascular magnetic resonance in a multicenter envir
201 olved blood oxygen level-dependent (CP-BOLD) cardiovascular magnetic resonance in detecting myocardia
205 and 27 healthy controls with multiparametric cardiovascular magnetic resonance including vasodilator
206 ge 65 years) underwent conventional clinical cardiovascular magnetic resonance, including late enhanc
207 es investigating the impact of correction of cardiovascular magnetic resonance indices for age and se
208 s as measured by late gadolinium enhancement cardiovascular magnetic resonance is an independent pred
209 ther athletic cardiac remodeling assessed by cardiovascular magnetic resonance is mediated by changes
212 tations that may be overcome by adding newer cardiovascular magnetic resonance mapping techniques.
214 are limited data on the prognostic value of cardiovascular magnetic resonance measurements in idiopa
215 Secondary efficacy outcomes included other cardiovascular magnetic resonance measures (LV end-diast
216 Consideration should be given to correcting cardiovascular magnetic resonance measures for age, sex,
217 Concordant with previous animal studies, cardiovascular magnetic resonance measures of contrast-e
218 circumference, were examined in relation to cardiovascular magnetic resonance measures of left ventr
219 Each participant underwent phase-contrast cardiovascular magnetic resonance measures of pulse wave
221 e were no between-group differences in other cardiovascular magnetic resonance measures, diuretic int
223 nal functional markers derived from standard cardiovascular magnetic resonance (MR) images for their
225 -pass perfusion and late gadolinium-enhanced cardiovascular magnetic resonance (MR) imaging to detect
228 e-related cardiotoxicity model, increases in cardiovascular magnetic resonance myocardial contrast-en
230 plications, accuracy, and reproducibility of cardiovascular magnetic resonance myocardial feature tra
231 g echocardiography (STE), and more recently, cardiovascular magnetic resonance myocardial feature tra
233 actice of monitoring cardiac iron in vivo by cardiovascular magnetic resonance of the midseptum.
234 single-photon emission computed tomography, cardiovascular magnetic resonance offers superior image
235 utaneous coronary intervention and underwent cardiovascular magnetic resonance on a 1.5-T scanner at
236 right ventricular structure and function by cardiovascular magnetic resonance on a 1.5-T Siemens sca
237 ic (Hemo+) infarctions, as determined by T2* cardiovascular magnetic resonance on day 3 (n=11), showe
238 ischemia-reperfusion injury (n=14) underwent cardiovascular magnetic resonance on days 3 and 56 after
239 ate gadolinium enhancement (LGE) assessed by cardiovascular magnetic resonance on left ventricular (L
241 ntrol study investigated crypts and 22 other cardiovascular magnetic resonance parameters in subclini
242 azard models adjusting for comorbidities and cardiovascular magnetic resonance parameters sought asso
243 emonstrated the usefulness of phase-contrast cardiovascular magnetic resonance (PC-CMR) in noninvasiv
244 ergoing PVR were prospectively recruited for cardiovascular magnetic resonance performed before PVR (
248 ng artificial intelligence quantification of cardiovascular magnetic resonance perfusion mapping prov
250 etected by late gadolinium enhancement (LGE) cardiovascular magnetic resonance predicts outcomes in p
251 xtracellular volume measures acquired during cardiovascular magnetic resonance promises to transform
252 nd G+P- subjects (n=23) underwent a clinical cardiovascular magnetic resonance protocol (3 tesla) for
254 of our study was to evaluate a comprehensive cardiovascular magnetic resonance protocol, including la
256 erload and provide calibration in humans for cardiovascular magnetic resonance R2* against myocardial
260 ts with a low pretest probability and normal cardiovascular magnetic resonance served as a control gr
261 ransposition of the great arteries, thus LGE cardiovascular magnetic resonance should be incorporated
262 t known heart failure successfully underwent cardiovascular magnetic resonance spectroscopy, yielding
263 indexed to body surface area was measured by cardiovascular magnetic resonance steady-state free prec
264 The LV parameters were measured from the cardiovascular magnetic resonance studies of the UK Biob
265 ed healthy controls) underwent comprehensive cardiovascular magnetic resonance studies, including nat
266 nts with constrictive pericarditis who had a cardiovascular magnetic resonance study with DHE prior t
268 tics Consortium (n = 188,577) and UK Biobank Cardiovascular Magnetic Resonance substudy (n = 16,923)
272 ship with outcomes, we used novel, validated cardiovascular magnetic resonance techniques to quantify
274 DM and 20 matched control subjects underwent cardiovascular magnetic resonance to assess LV remodelin
277 ations, the authors discuss the potential of cardiovascular magnetic resonance to inform treatment du
279 Beyond accurate diagnosis, the value of cardiovascular magnetic resonance to predict the outcome
280 ical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and a
281 the clinical performance of adenosine stress cardiovascular magnetic resonance using this new perfusi
282 s showed that the absence of LGE at baseline cardiovascular magnetic resonance was a strong predictor
284 The relationship between ECG strain and cardiovascular magnetic resonance was then assessed in a
287 as >=12% increase in both LVESV and LVEDV by cardiovascular magnetic resonance, was associated with w
289 onischemic dilated cardiomyopathy undergoing cardiovascular magnetic resonance were followed for the
291 ated to estimate myocardium at risk (MaR) by cardiovascular magnetic resonance while using myocardial
295 nal intensities evident on contrast-enhanced cardiovascular magnetic resonance with late gadolinium e
296 l study participants underwent comprehensive cardiovascular magnetic resonance with T1 and T2 mapping
297 ial infarction with paired acute and 6-month cardiovascular magnetic resonance, with the 5-year compo
298 nical assessment, ECG, and contrast-enhanced cardiovascular magnetic resonance within a week of their
299 ited 793 consecutive patients at the time of cardiovascular magnetic resonance without amyloidosis or
300 hypothesized that noncontrast T1 mapping by cardiovascular magnetic resonance would provide a novel